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http://dx.doi.org/10.1016/j.jmii.2013Background: Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granu-
lomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and ChurgeStrauss syndrome
(CSS), comprises a group of diseases with significant morbidity and mortality. The incidence
and relative frequency of GPA/MPA/CSS are different all over the world. The epidemiology
of AAV in Taiwan is still not clear.
Methods: The current study aimed to provide a population-based estimate of the annual inci-
dence of GPA using the Taiwan National Health Insurance (NHI) research database and a single
hospital-based estimate of the relative frequency of AAV in Taiwan.
Results: The annual incidence of GPA in Taiwan was 0.37 per million patient-years (95% Poisson
rate confidence interval: 0.30e0.45) from 1997 to 2008, according to the NHI database. In our
hospital, 24 patients were newly diagnosed with AAV between 2003 and 2011, including eight
patients with GPA, 14 with MPA, and two with CSS. The ratio of the number of patients with
GPA to that of MPA was 0.57.
Conclusion: The current results provide an estimate of the annual incidence of GPA and the
relative frequency of AAV in the Chinese Han community in Taiwan. Such geoepidemiologyt of Internal Medicine, Far Eastern Memorial Hospital, Number 21, Section 2, Nan-Ya South Road,
Taiwan.
rg.tw (C.-S. Wu).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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478 C.-S. Wu et al.information may help illuminate the interaction between ethnic background and environment
in these autoimmune diseases.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Antineutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV), including granulomatosis with polyangiitis
(GPA; previously known as Wegener’s granulomatosis),
microscopic polyangiitis (MPA), and ChurgeStrauss syn-
drome (CSS), comprises a group of rare diseases associated
with high morbidity and mortality. The timely diagnosis of
any of these conditions is difficult due to their rare occur-
rence and variable clinical manifestations. The clinical
diagnosis of AAV is facilitated by the recent availability of
an enzyme-linked immunosorbent assay (ELISA) for ANCA,
which has provided improved specificity compared with an
indirect immunofluorescence assay.1e3 The reported inci-
dence of GPA, MPA, and CSS varies significantly all over the
world. A north-to-south gradient of the GPA/MPA ratio is
believed to exist according to the European data. For
example, the incidence ratio of GPA/MPA is increased in
Norway [incidence of GPA and MPA: 10.5 per million and 2.7
per million, respectively (ratio 3.9)] and decreased in Spain
[incidence of GPA and MPA: 4.9 per million and 11.6 per
million, respectively (ratio 0.42)].4 Non-Caucasian epide-
miological studies of AAV remain limited; a study in Japan
showed that MPA comprises up to 83% of AAV.5 Therefore,
an examination of the incidence of AAV across ethnicities
and geographic regions in Taiwan may help reveal the
interaction between genetic and environmental compo-
nents as contributing factors to these complex diseases.
There is a paucity of research examining AAV in
Taiwan.6,7 The Taiwan National Health Insurance (NHI), a
single health insurance provider for citizens of Taiwan since
1995, is a good data source for the epidemiologic study of
these rare diseases. The NHI Research Database uses the
Ninth Revision of the International Classification of Diseases
(ICD-9) for disease registry. At the time of data collection,
only GPA had an ICD-9 code and data on the incidence of
MPA or CSS were not available in the NHI database. The
incidence of MPA or CSS may be estimated from the relative
frequency of GPA, MPA, and CSS. This study aimed to esti-
mate the incidence of GPA using the Taiwan NHI database
analysis and to derive the relative incidence of AAV (GPA/
MPA/CSS) as well as the clinical characteristics of these
patients from a single-center experience.Methods
National Health Insurance Research Database
The total number of patients with GPA and the annual
incidence rate were derived from the NHI Research Data-
base. In 2008, the NHI provided coverage for a population of
nearly 23 million (approximately 99.5% of the population).
The NHI research database includes all claim information ofoutpatients, inpatients, and emergency departments.8 GPA
(ICD-9 446.4) and end-stage renal disease (ESRD; ICD-9 585)
that require renal replacement therapy are listed as cata-
strophic diseases in the NHI database. Patients with these
severe diseases are exempt from a copayment at the time
of care. In addition, the catastrophic disease registry is
under the regulation of the NHI authority.
For the current study, the catastrophic illness file of the
NHI claims data was used for analysis. We selected the
patients who were diagnosed with GPA (ICD-9 446.4) be-
tween 1997 and 2008. The incident date was defined by the
date of catastrophic illness certification. The annual inci-
dence rate was defined as the number of new cases divided
by the number of person-years observed during a given time
period. Sex and age at diagnosis were obtained. The num-
ber of patients with ESRD and GPA, and the time interval
between the diagnosis of ESRD and GPA were also
calculated.
Generation of patient lists in the hospital-based
study
Between October 2003 and October 2011, a list of patients
diagnosed with AAV was generated from computerized da-
tabases of serology, pathology, electronic chart record
system, and consultation records in the Far Eastern Me-
morial Hospital, New Taipei City, Taiwan. Patients with a
creatinine clearance of less than 15 mL/minute were clas-
sified as having ESRD. All study protocols were approved by
the Institutional Review Board of the Far Eastern Memorial
Hospital (FEMH-IRB-100165-E).
Case ascertainment and classification
Complete chart reviews revealed patient demographic
data, including sex, age at diagnosis, initial presentations,
ANCA status, treatment, and prognosis. Clinical records of
surrogate markers such as sinusitis, image studies of lung,
urine analysis, and pathology reports were reviewed care-
fully. Proteinase 3 ANCA (PR3-ANCA) and myeloperoxidase
ANCA (MPO-ANCA) were tested using commercial ELISA kits
(EliA PR3 and EliA MPO; Phadia AB, Uppsala, Sweden). We
followed the European Medicines Agency (EMEA) algorithm
to avoid overlapping of cases and to ensure consistency of
classification across studies.9
Statistical analysis
The annual incidences of GPA in each 3-year interval be-
tween 1997 and 2008 were calculated. The 95% confidence
intervals of Poisson rate were calculated for each period
using StatsDirect Version 2.7.9 (StatsDirect Ltd, Altrincham,
UK).
Table 2 Incidence of GPA (per million patient-years) in
Taiwan, 1997e2008
Years Cases Incidence 95% CI
1997e1999 17 0.27 0.16e0.44
2000e2002 14 0.22 0.12e0.36
2003e2005 34 0.51 0.35e0.72
2006e2008 31 0.46 0.31e0.65
All 96 0.37 0.30e0.45
GPA Z granulomatosis with polyangiitis; 95% CI Z 95% Poisson
rate confidence interval.
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GPA in the NHI research database
A total of 96 patients with GPA were identified using the NHI
database between 1997 and 2008. The distribution of pa-
tient age and sex is shown in Table 1. The average patient
age was 49.72  16.27 years (males: 47.30  14.94 years of
age; females: 52.35  17.38 years of age), with a male to
female ratio of 1.09. The incidence of GPA was 0.37 per
million patient-years (95% Poisson rate confidence interval
0.30e0.45). The incidence between 2003 and 2008 was
higher than that reported between 1997 and 2002 (Table 2).
ESRD occurred in two patients prior to and in four patients
after the diagnosis of GPA. The time to ESRD after the
diagnosis of GPA ranged from 10 months to 46 months.Table 3 Clinical manifestations of patients with ANCA-
associated vasculitis
GPA
(n Z 8)
MPA
(n Z 14)
CSS
(n Z 2)
Age 50.9  17.6 57.4  17.8 43
Sex (M:F) 6:2 6:8 1:1
Anti-PR3 5 (62.5) 5 (35.7) 0 (0)
Anti-MPO 3 (37.5) 11 (78.6) 0 (0)Patient characteristics and clinical manifestations
in the hospital-based study
Between October 2003 and October 2011, a total of 24
patients with AAV were classified based on the EMEA algo-
rithm (Fig. 1), including eight patients with GPA, 14 pa-
tients with MPA, and two individuals with CSS. For
diagnosis, sinus biopsy was performed in four out of eight
patients with GPA, renal biopsy in one out of eight patients
with GPA and in four out of 14 patients with MPA, and skin
biopsy in one patient with GPA, two individuals with MPA,
and one individual with CSS.
The initial presentation of eight patients with GPA was
as follows: seven patients with sinusitis, two patients with
hematuria, one individual with cranial neuropathy, and one
individual with episcleritis. In a total of 14 patients with
MPA, six patients had hemoptysis or pulmonary hemor-
rhage, nine patients had hematuria, and two individuals
had neuropathy. Three patients had a cerebrovascular ac-
cident prior to a diagnosis of MPA. Additional clinical fea-
tures are summarized in Table 3. Patients with MPA were
older than those with GPA and CSS. PR3-ANCA was more
prevalent in GPA, whereas MPO-ANCA was more prevalent
in MPA. Both patients with CSS were ANCA negative.
As part of the treatment regimen, corticosteroids were
used in 19 out of 24 patients with AAV. Cyclophosphamide
was given in about half of patients (6 out of 8 patients with
GPA, 5 out of 14 patients with MPA, and 2 out of 2 patientsTable 1 Age and sex distribution of GPA in Taiwan,
1997e2008
Age (y) Male Female Total
<20 1 4 5
21e30 9 1 10
31e40 5 6 11
41e50 9 6 15
51e60 17 13 30
61e70 5 10 15
71e80 4 6 10
All 50 46 96
GPA Z granulomatosis with polyangiitis.with CSS). Plasma exchange was performed in three pa-
tients with MPA; two individuals died (1 due to sepsis and 1
due to pulmonary hemorrhage) despite the plasma ex-
change, and the remaining one progressed to ESRD.
Glucocorticoid and cyclophosphamide were used in two
patients with CSS for skin papules and persistent sinusitis.
Pulmonary involvement was revealed by chest roent-
genography or computed tomography in seven out of eight
patients with GPA and in 11 out of 14 patients with MPA.
Pulmonary hemorrhage was present in three out of eight
patients with GPA and in seven out of 14 patients with MPA.
Asthma developed 2 years prior to the diagnosis of CSS in
the two patients.
At diagnosis, the median (range) serum creatinine level
was higher in patients with MPA [3.1 (0.7e8.4) mg/dL]
compared to patients with GPA [1 (0.7e1.8) mg/dL]. As a
part of the study follow-up, kidney involvement (e.g., he-
maturia, proteinuria, or elevated creatinine) was found in
all patients with MPA and in two out of eight patients with
GPA. ESRD occurred in eight out of 14 of patients with MPA
at diagnosis, and long-term renal replacement therapy was
required in four of the nine survivors. One patient with GPAClinical manifestations
Lung involvement 7 (87.5) 11 (78.6) 2 (100)
ESRD 1 (12.5) 8 (57.1) 0 (0)
Neuropathy 2 (25) 3 (21) 2 (100)
Mortality 1 (12.5) 5 (35.7) 0 (0)
Treatment
Glucocorticoid 8 (100) 9 (64.2) 2 (100)
Cyclophosphamide 6 (75) 5 (35.7) 2 (100)
Plasma exchange 0 (0) 3 (21.4) 0 (0)
Data are presented as n (%) or mean  SD, unless otherwise
specified.
ANCA Z antineutrophil cytoplasmic antibody;
CSS Z ChurgeStrauss syndrome; ESRD Z end-stage renal dis-
ease; GPA Z granulomatosis with polyangiitis;
MPA Z microscopic polyangiitis; PR3 Z proteinase 3.
Figure 1. Classification algorithm. AAV Z ANCA associated vasculitis; ACR Z American College of Rheumatology;
ANCA Z antineutrophil cytoplasmic antibody; CHCC Z Chapel Hill Consensus Conference; CSS Z ChurgeStrauss syndrome;
GPA Z granulomatosis with polyangiitis; MPA Z microscopic polyangiitis.
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renal failure was noted in our patients with CSS.
Five out of the 14 patients with MPA died (2 from pul-
monary hemorrhage, 2 from sepsis, and 1 from intracranial
hemorrhage during sepsis). Among the eight patients with
GPA, one died due to acute coronary syndrome. In the six
patients with AAV who died, the median (range) interval to
time of death post diagnosis was 26.5 (2e67) days. No
deaths occurred in two patients with CSS, despite intra-
cranial hemorrhage reported in one patient.Discussion
In our study, the annual incidence of GPA was 0.37 per
million between 1997 and 2008, according to the NHIdatabase. In Hong Kong, the annual incidence of GPA has
been estimated to be <2 per million.10 Therefore, the
incidence of GPA in the Chinese Han population is much
lower than that observed in a Caucasian population.4
However, the incidence of GPA varies greatly, even in a
Caucasian population. For example, the incidence of GPA in
Vilnius (the capital city), Lithuania, is 2 per million,11 which
is less than that observed in other European cities.4 The
observed incidence may change due to the availability of
serologic tests and the awareness of treating physicians.
Nevertheless, the currently available NHI data included
12 years of records, and we believe that the reported
incidence of GPA is the best available description of inci-
dence rates in a Chinese Han population.
Another important issue is whether the northesouth
gradient observed for the GPA/MPA incidence ratio exists in
ANCA-associated vasculitis in Taiwan 481populations other than a Caucasian population. According
to the European data, the GPA/MPA incidence ratio is
elevated in northern Europe compared with that in south-
ern Europe.4 Our data may provide an opportunity to
examine this hypothesis further in a non-Caucasian popu-
lation. According to studies in a Chinese Han population,
the GPA to MPA ratio can range from 0.17 in a nephrologist-
initiated study12 to 0.66 in a rheumatologist-initiated
study13 (Table 4). A recent study in Beijing (latitude
39.9N) that applied the EMEA algorithm revealed a GPA to
MPA ratio of roughly 0.6014dwhich is similar to our study in
New Taipei City (ratio 0.57; latitude 25.01N). However,
previous studies did not specify whether the reported cases
were diagnosed newly or whether those relative fre-
quencies were representative of the relative prevalence of
AAV. Based on the currently available data, the issue of
northesouth gradient remains unresolved in Chinese Han
societies.
A previous study in China showed that MPO-ANCA is more
prevalent in patients with GPA,14 whereas another study
showed a greater prevalence of PR3-ANCA.12 In the current
study, the patients with GPA demonstrated an increased
prevalence of PR3-ANCA. Another study of GPA patients in
Taiwan revealed a predominant cytoplasmic ANCA pattern,
which has been demonstrated to be associated strongly
with PR3-ANCA.6 Taken together, these results suggest
similarities in the pattern of ANCA serology of GPA in a
Taiwanese population compared with a Caucasian
population.
MPA is more prevalent in Asia and seemed to be associ-
ated with higher mortality. MPA resulted in death in five out
of 14 (35.7%) patients in the current study, which is closer
to the proportion reported by Chen et al12 [20 out of 84
patients with MPA (24%), with renal limited glomerulone-
phritis reclassified as MPA], but higher than that observed in
a Caucasian population (0e23%).15 In the current study,
ESRD requiring long-term dialysis occurred in four out of the
nine survivors. Mortality associated with GPA (12.5%) was
not as high as that of MPA in our series. However, in aTable 4 Relative frequency of GPA, MPA, and CSS in
hospital-based studies in Chinese Han societies
Total
cases
GPA MPA CSS GPA/
MPA
Hung et al,7
Taipeia
18 4 (22.2) 14 (77.8) 0 (0) 0.29
Liu et al,14
Beijingb
530 199 (37.5) 329 (62.1) 2 (0.4) 0.60
Chen et al,12
Shanghaia
101 14 (13.9) 84 (83.2) 3 (2.9) 0.17
Zhang et al,13
Beijing
179 61 (34.0) 93 (52.0) 25 (14.0) 0.66
This study 24 8 (33.3) 14 (58.3) 2 (8.3) 0.57
a Renal limited vasculitis was reclassified as MPA according to
the EMEA algorithm.
b Excluding unclassifiable patients.
Data are presented as n (%).
CSS Z ChurgeStrauss syndrome; EMEA Z European Medicines
Agency; GPA Z granulomatosis with polyangiitis;
MPA Z microscopic polyangiitis.single-center study of GPA between 1985 and 2005 in
Taiwan, a high mortality rate approaching 50% was re-
ported.6 As reported by Chen et al,12 six out of 14 patients
with GPA died (43%); half of these cases can be attributed
to infection.
In our study, the relative frequency of CSS in AAV is
similar to that reported by Zhang et al13 (Table 4). In
Taiwan, CSS is rare and only a few CSS case reports are
available.16e19 Most of these cases presented with more
severe manifestations such as intracranial hemorrhage and
multiple gastrointestinal ulcers, which was probably due to
publication bias. However, one of our patients suffered
from intracranial hemorrhage, demonstrating that CSS may
be associated with significant morbidity.
Limitations to the current study are as follows. First, the
incidence rates derived from the NHI database may be
flawed due to incomplete coding or misclassification. It is
not with absolute certainty that the ESRD cases in the
database study can be attributed solely to GPA. Second, our
clinical AAV series was small and represented only a single-
center experience. Outcomes such as mortality or ESRD
should be interpreted carefully due to a relatively short
follow-up time.
In conclusion, our study provides a population-based
estimate of the incidence of GPA in Taiwan. We also provide
a hospital-based estimate of the relative frequency of AAV.
All cases were diagnosed newly, which provided a good
estimate of the relative incidence of AAV. Although biopsies
were not performed in all patients, the use of a standard-
ized EMEA algorithm provided a reliable classification for
comparison with previously published studies. The geo-
epidemiology information may help illuminate the inter-
action between ethnic background and environment in
autoimmune diseases like AAV.
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